Arbutus Biopharma Reports Strong Q1 Net Income of $169.7M Driven by Moderna Settlement Revenue
ABUS sits 51% above its 52-week low of $2.94.
Summary
Arbutus Biopharma announced robust first-quarter financial results, reporting a net income of $169.7 million, largely due to the $178.7 million license revenue from the Moderna patent settlement.
Key Events · Earnings and Guidance · ABUS
-
Strong Q1 Financial Performance
The company reported a net income of $169.7 million ($0.88 per basic share) for Q1 2026, a significant improvement from a $24.5 million net loss in Q1 2025.
-
Substantial Revenue from Moderna Settlement
Total revenue for Q1 2026 was $179.1 million, primarily due to $178.7 million in license revenue from Genevant, representing Arbutus's portion of the upfront Moderna patent settlement payment expected in July 2026.
-
Strengthened Cash Position
Cash, cash equivalents, and marketable securities stood at $95.2 million as of March 31, 2026, with an additional $178.7 million license receivable from Genevant, significantly boosting the company's financial liquidity.
-
Imdusiran Receives Fast Track Designation
The U.S. FDA granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B, a positive development previously announced on April 15, 2026.
Analysis · ABUS · Life Sciences
Arbutus Biopharma reported a significant net income of $169.7 million for Q1 2026, a substantial turnaround from a loss in the prior year, primarily driven by $178.7 million in license revenue from the Moderna patent settlement. This confirms the material financial benefits of the settlement, significantly strengthening the company's balance sheet and providing a strong cash runway.
At the time of this filing, ABUS was trading at $4.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $848.8M. The 52-week trading range was $2.94 to $5.10. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.